Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma

被引:69
作者
Kino, T
Takeshima, H [1 ]
Nakao, M
Nishi, T
Yamamoto, K
Kimura, T
Saito, Y
Kochi, M
Kuratsu, J
Saya, H
Ushio, Y
机构
[1] Kagoshima Univ, Fac Med, Dept Neurosurg, Kagoshima 8908520, Japan
[2] Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 8608556, Japan
关键词
D O I
10.1046/j.1365-2443.2001.00432.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: Although mutational inactivation and allelic loss in the NF2 gene appear to be causal events in the majority of vestibular schwannomas, involvement of another potentially important mechanism, transcriptional inactivation, has not been investigated. Results: We cloned and functionally characterized the 5'-flanking region of the human NF2 gene and identified the molecular mechanisms that regulate NF2 expression. Luciferase assay and site-directed mutagenesis demonstrated that a 70-base pair (bp) region (-591 to -522 bp from the translation start site) was essential for the basic expression of the NF2 gene. A gel mobility shift assay indicated recognition by nuclear protein of the unusually long (approximate to 66 bp) sequences in this region. Recognition was inhibited by either mutation of the binding core sequence or by methylation of three CpG sites. Point mutations at these CpG sites significantly decreased promoter activity, suggesting the importance of these sites. In 14 of 23 vestibular schwannomas, these three CpG sites were methylated in a site-specific manner and the methylation status was consistent with the expression of NF2 mRNA. Conclusions: Suppressed expression by aberrant methylation or mutation of the promoter elements could be an alternative mechanism for inactivation of the NF2 gene.
引用
收藏
页码:441 / 454
页数:14
相关论文
共 27 条
[1]  
Bergman Y, 1998, BIOL CHEM, V379, P401
[2]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[3]  
DeVitis LR, 1996, HUM GENET, V97, P632
[4]  
Eldridge R, 1981, Adv Neurol, V29, P57
[5]  
Fujita N, 1999, MOL CELL BIOL, V19, P6415
[6]  
GREGOR V, 1988, HUM GENET, V83, P155
[7]   Overview of RB gene mutations in patients with retinoblastoma - Implications for clinical genetic screening [J].
Harbour, JW .
OPHTHALMOLOGY, 1998, 105 (08) :1442-1447
[8]   SILENCING OF THE VHL TUMOR-SUPPRESSOR GENE BY DNA METHYLATION IN RENAL-CARCINOMA [J].
HERMAN, JG ;
LATIF, F ;
WENG, YK ;
LERMAN, MI ;
ZBAR, B ;
LIU, S ;
SAMID, D ;
DUAN, DSR ;
GNARRA, JR ;
LINEHAN, WM ;
BAYLIN, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :9700-9704
[9]   CPG METHYLATION OF THE CAMP-RESPONSIVE ENHANCER PROMOTER SEQUENCE TGACGTCA ABOLISHES SPECIFIC FACTOR BINDING AS WELL AS TRANSCRIPTIONAL ACTIVATION [J].
IGUCHIARIGA, SMM ;
SCHAFFNER, W .
GENES & DEVELOPMENT, 1989, 3 (05) :612-619
[10]   Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15(INK4B)) in childhood acute lymphoblastic leukemia [J].
Iravani, M ;
Dhat, R ;
Price, CM .
ONCOGENE, 1997, 15 (21) :2609-2614